Rhodiola rosea as an adaptogen to enhance exercise performance: a review of the literature

Rhodiola rosea (RR) is a plant whose bioactive components may function as adaptogens, thereby increasing resistance to stress and improving overall resilience. Some of these effects may influence exercise performance and adaptations. Based on studies of rodents, potential mechanisms for the ergogenic effects of RR include modulation of energy substrate stores and use, reductions in fatigue and muscle damage and altered antioxidant activity. At least sixteen investigations in humans have explored the potential ergogenicity of RR. These studies indicate acute RR supplementation (∼200 mg RR containing ∼1 % salidroside and ∼3 % rosavin, provided 60 min before exercise) may prolong time-to-exhaustion and improve time trial performance in recreationally active males and females, with limited documented benefits of chronic supplementation. Recent trials providing higher doses (∼1500 to 2400 mg RR/d for 4–30 d) have demonstrated ergogenic effects during sprints on bicycle ergometers and resistance training in trained and untrained adults. The effects of RR on muscle damage, inflammation, energy system modulation, antioxidant activity and perceived exertion are presently equivocal. Collectively, it appears that adequately dosed RR enhances dimensions of exercise performance and related outcomes for select tasks. However, the current literature does not unanimously show that RR is ergogenic. Variability in supplementation dose and duration, concentration of bioactive compounds, participant characteristics, exercise tests and statistical considerations may help explain these disparate findings. Future research should build on the longstanding use of RR and contemporary clinical trials to establish the conditions in which supplementation facilitates exercise performance and adaptations.

Authenticity and quality evaluation of different Rhodiola species and commercial products based on NMR-spectroscopy and HPLC

INTRODUCTION

The main concern regarding the authenticity and quality of Rhodiola rosea L. (Sedum rosea (L.) Scop.) products is their adulteration with other Rhodiola species.

OBJECTIVE

The aim of the study was the development of a reliable and practical analytical platform for quality and quantity assessment of the characteristic molecules in three Rhodiola species (R. rosea, R. kirilowii (Regel) Maxim and R. crenulata (Hook. f. & Thomson) H. Ohba), commercial products and their possible application as markers for the authentication of R. rosea based products.

MATERIAL AND METHODS

The major molecules were identified by one-dimensional (1D) and two-dimensional (2D) nuclear magnetic resonance (NMR)-based metabolomics and quantitatively determined by high-performance liquid chromatography ultraviolet (HPLC-UV) analysis. The orthogonal projections to latent structures discriminant analysis (OPLS-DA) revealed the specific patterns in the metabolite profiles of R. rosea and R. crenulata.

RESULTS

The coumarin crenulatin was only identified in R. crenulata and can be used as a marker to detect potential adulteration of the commercial products. Crenulatin was identified in two of the four analysed products by NMR-spectroscopy. According to the HPLC data, in less than a quarter of all products, the labelled amounts of salidroside and total rosavins were confirmed.

CONCLUSIONS

The developed analytical platform was found to be useful in the investigations of the phytochemical diversity of different Rhodiola species, the recognition of the unique metabolites between them and the identification of adulterated products. Therefore, this approach could be applied from the earliest to the latest stages of the value chain in the manufacturing of R. rosea based products.

Altered expression of TRAIL on mouse T cells via ERK phosphorylation by Rhodiola rosea L. and its marker compounds

Rhodiola rosea L. extracts have shown neuroprotective, anti-fatigue, anti-inflammatory and anti-tumor properties. However, the studies on their effect on T cell function are rather scarce. We examined the potential of R. rosea extract and its major constituents - salidroside, rosarin, rosavin and rosin to alter cell growth of human Jurkat T cells, apoptosis of splenic mouse CD3 T cells and expression of the surface markers and phosphorylation of extracellular signal-regulated kinase (ERK). The initial screening for cell viability in Jurkat T cells and for apoptosis of mouse T cells showed the strongest activity for rosavin and rosarin. Rosarin and rosavin did not alter significantly the dynamic of CD69 expression upon stimulation, but altered TNF-related apoptosis-inducing ligand (TRAIL) expression. Rosavin inhibited TRAIL up-regulation, while rosarin showed an opposite effect. Indeed, rosarin increased the frequencies of CD3⁺TRAIL⁺ T cells and the fold inhibition of ERK phosphorylation. Our data showed that different effects of rosarin and rosavin on TRAIL expression can involve distinct action on ERK signaling and hence highlighted their potential to manipulate TRAIL as a tool to rescue the resistance to apoptosis in autoimmune diseases and cancer.